GRAIL

GRAIL is a pioneering healthcare company founded in 2015, specializing in medical testing and clinical laboratory services. The organization is dedicated to transforming cancer screening through its innovative Galleri test, which utilizes advanced methylation analysis and machine-learning algorithms to enable multi-cancer early detection (MCED) by analyzing DNA in the bloodstream. By focusing on proactive screening solutions, GRAIL aims to significantly reduce cancer mortality rates and change the trajectory of patient outcomes. The company serves a diverse range of stakeholders, including oncologists, healthcare providers, and individuals seeking early diagnostic insights.

Operating with a workforce of 500-1,000 employees, GRAIL maintains a robust operational footprint focused on biotechnology and diagnostic innovation. The company leverages a multidisciplinary team of scientists, engineers, and medical professionals to drive its research and development efforts. Meet GRAIL's team to learn about the leadership and technical expertise driving their mission. Their commitment to high-quality data and actionable insights positions them as a leader in the liquid biopsy market, competing with firms like Freenome and Guardant. The company’s focus on innovation-driven diagnostics continues to shape the future of personalized medicine.

GRAIL has secured significant capital through multiple funding rounds, including Series A through Series D, supported by prominent investors such as Illumina, Amazon, and various venture capital firms. With a reported revenue of $165.3M, the company demonstrates strong market presence and financial stability within the competitive healthcare landscape. Explore financial highlights for detailed metrics regarding their fiscal performance and growth trajectory. As a NASDAQ-listed entity (NASDAQ: GRAL), GRAIL continues to scale itsView more...